Human igm antibody lysing activated lymphocytes under mediation by homologous complement
OwnerHidechika Okada, Noriko Okadainventors
Life of this patent
Estimating the term…
Loading patent…
OwnerHidechika Okada, Noriko Okadainventors
Estimating the term…
A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection
A human IgM monoclonal antibody reactive to activated human lymphocytes and HIV-infected cells for lysing cells under mediation by homologous human complements.
An immunosuppressant and HIV remedy for treating transplantation rejection responses and autoimmune diseases caused by excessive reaction of T-lymphocytes, whereby abnormally activated lymphocytes are eliminated by cytolysis using a human IgM monoclonal antibody reactive to activated human lymphocytes.
A cell strain with an accession No. of FERM PB-8379 that produces the human IgM monoclonal antibody reactive to the activated human lymphocytes and HIV-infected cells that lyses the cells under mediation by a homologous human complement.
Dependencies are inferred from the claim text.